Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology

Temming, K.; Lacombe, M.; van der Hoeven, P.; Pradash, J.; Gonzalo, T.; Dijkers, E.C.F.; Orfi, L.; Keri, G.; Poelstra, K.; Molema, G.; Kok, R.J.

Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology

DSpace/Manakin Repository

Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology

Temming, K.; Lacombe, M.; van der Hoeven, P.; Pradash, J.; Gonzalo, T.; Dijkers, E.C.F.; Orfi, L.; Keri, G.; Poelstra, K.; Molema, G.; Kok, R.J.

(2006) Bioconjugate Chemistry, volume 17, pp. 1246 - 1255

(Article)

Download/Full Text

Open Access version via Utrecht University Repository

Publisher version

Keywords: Medical technology, Farmacie(FARM), Biomedische technologie en medicijnen, Pharmacology

ISSN: 1043-1802

Publisher: American Chemical Society : Division of Carbohydrate Chemistry

(Peer reviewed)

See more statistics about this item